Express Scripts Holding (NASDAQ:ESRX) – Equities research analysts at William Blair upped their Q1 2018 EPS estimates for shares of Express Scripts in a note issued to investors on Tuesday, according to Zacks Investment Research. William Blair analyst J. Kreger now forecasts that the company will earn $1.93 per share for the quarter, up from their previous estimate of $1.61. William Blair also issued estimates for Express Scripts’ Q2 2018 earnings at $2.37 EPS, Q3 2018 earnings at $2.44 EPS, Q4 2018 earnings at $2.63 EPS, FY2018 earnings at $9.37 EPS, Q1 2019 earnings at $2.17 EPS, Q2 2019 earnings at $2.49 EPS, Q3 2019 earnings at $2.68 EPS, Q4 2019 earnings at $2.95 EPS, FY2019 earnings at $10.28 EPS, FY2020 earnings at $9.10 EPS and FY2021 earnings at $8.10 EPS.
ESRX has been the topic of a number of other research reports. Robert W. Baird raised their price objective on shares of Express Scripts from $57.00 to $59.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Zacks Investment Research downgraded shares of Express Scripts from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Royal Bank of Canada set a $66.00 price objective on shares of Express Scripts and gave the stock a “hold” rating in a report on Wednesday, October 25th. UBS Group downgraded shares of Express Scripts from a “market perform” rating to an “underperform” rating in a report on Monday, October 9th. Finally, TheStreet upgraded shares of Express Scripts from a “c+” rating to a “b-” rating in a research note on Monday, December 4th. Six analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Express Scripts presently has an average rating of “Hold” and a consensus target price of $78.23.
Express Scripts (ESRX) traded down $1.60 on Thursday, hitting $76.50. 3,444,054 shares of the company were exchanged, compared to its average volume of 4,184,672. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.61 and a current ratio of 0.73. The stock has a market capitalization of $44,230.00, a P/E ratio of 12.71, a price-to-earnings-growth ratio of 0.88 and a beta of 0.93. Express Scripts has a one year low of $55.80 and a one year high of $83.49.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CIBC Asset Management Inc boosted its stake in Express Scripts by 4.3% during the fourth quarter. CIBC Asset Management Inc now owns 78,226 shares of the company’s stock worth $5,839,000 after buying an additional 3,221 shares during the period. Rockefeller Financial Services Inc. boosted its stake in Express Scripts by 7.9% during the fourth quarter. Rockefeller Financial Services Inc. now owns 22,131 shares of the company’s stock worth $1,652,000 after buying an additional 1,629 shares during the period. C M Bidwell & Associates Ltd. purchased a new position in Express Scripts during the fourth quarter worth $403,000. SeaCrest Wealth Management LLC purchased a new position in Express Scripts during the fourth quarter worth $105,000. Finally, Hemenway Trust Co LLC purchased a new position in Express Scripts during the fourth quarter worth $222,000. Institutional investors own 88.19% of the company’s stock.
In related news, VP Glen D. Stettin sold 3,449 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $81.00, for a total value of $279,369.00. Following the sale, the vice president now owns 33,715 shares in the company, valued at $2,730,915. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Christine Houston sold 10,104 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $70.08, for a total transaction of $708,088.32. Following the completion of the sale, the vice president now owns 87,400 shares in the company, valued at approximately $6,124,992. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,001 shares of company stock worth $1,249,505. Company insiders own 0.68% of the company’s stock.
Express Scripts declared that its board has approved a stock repurchase program on Monday, December 18th that permits the company to buyback 45,000,000 shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/02/express-scripts-holding-expected-to-post-q1-2018-earnings-of-1-93-per-share-esrx.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Get a free copy of the Zacks research report on Express Scripts (ESRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.